Ke Ding

15.0k total citations · 2 hit papers
332 papers, 10.8k citations indexed

About

Ke Ding is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Ke Ding has authored 332 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Molecular Biology, 85 papers in Oncology and 81 papers in Organic Chemistry. Recurrent topics in Ke Ding's work include Cancer therapeutics and mechanisms (34 papers), Protein Degradation and Inhibitors (34 papers) and Lung Cancer Treatments and Mutations (29 papers). Ke Ding is often cited by papers focused on Cancer therapeutics and mechanisms (34 papers), Protein Degradation and Inhibitors (34 papers) and Lung Cancer Treatments and Mutations (29 papers). Ke Ding collaborates with scholars based in China, United States and Thailand. Ke Ding's co-authors include Xiaoyun Lu, Xiaomei Ren, Shaomeng Wang, Zhang Zhang, Jeff B. Smaill, Qian Cai, Jingxuan Pan, Zhengchao Tu, Zaneta Nikolovska‐Coleska and Fengtao Zhou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Ke Ding

318 papers receiving 10.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

2006 602 citations Ke Ding, Yipin Lu et al. Journal of Medicinal Chemistry profile →
Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors

2005 564 citations Ke Ding, Yipin Lu et al. profile →

Peers

Countries citing papers authored by Ke Ding

Since Specialization

Citations

This map shows the geographic impact of Ke Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Ding more than expected).

Fields of papers citing papers by Ke Ding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ke Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Ding. The network helps show where Ke Ding may publish in the future.

Co-authorship network of co-authors of Ke Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Ke Ding. A scholar is included among the top collaborators of Ke Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ke Ding. Ke Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance 2025 ·Accounts of Chemical Research ·Ke Ding, Yupeng Li, Yang Zhou, Weixue Huang	0
2	Protective effect of selenomethionine on rabbit testicular injury induced by Aflatoxin B1 2024 ·The Science of The Total Environment ·(unknown), Ziqiang Zhang, Shiyang Liu, (unknown), (unknown), (unknown), Ke Ding, Yumei Liu	7
3	Catalyst-free late-stage functionalization to assemble α-acyloxyenamide electrophiles for selectively profiling conserved lysine residues 2024 ·Communications Chemistry ·(unknown), (unknown), (unknown), Shengrong Li, Liyan Huang, Zhengchao Tu, Hongyan Sun, Gregory M. Cook, Jing Yang, Pinghua Sun, Yi Tan, Ke Ding, Zhengqiu Li	10
4	Regulation of histidine metabolism by Lactobacillus Reuteri mediates the pathogenesis and treatment of ischemic stroke 2024 ·Acta Pharmaceutica Sinica B ·(unknown), (unknown), (unknown), Jijun Xiao, (unknown), Ke Ding, Tingting Zhang, Guangji Wang, Haiping Hao, Yan Liang	4
5	Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization 2024 ·Biochemical and Biophysical Research Communications ·Xiaocheng Gong, Yunfei Liu, Keying Liang, Zixi Chen, Ke Ding, Qiu Li, Jinfen Wei, Hongli Du	3
6	Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader 2024 ·Journal of Medicinal Chemistry ·(unknown), Abhijit Parolia, Yihan Liu, (unknown), (unknown), Yuanyuan Qiao, Sanjana Eyunni, (unknown), Chungen Li, Yongxing Wang, Fengtao Zhou, Weixue Huang, Xiaomei Ren, Zhen Wang, Arul M. Chinnaiyan, Ke Ding	13
7	Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia 2023 ·European Journal of Medicinal Chemistry ·Wenyan Liu, Yu Bai, Licheng Zhou, Jian Jin, Meiying Zhang, Yongxing Wang, (unknown), Weixue Huang, Xiaomei Ren, Nan Ma, Fengtao Zhou, Zhen Wang, Ke Ding	13
8	Targeting GAS6/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer 2023 ·Life Sciences ·Tae Hoon Kim, (unknown), Hye Jeong Oh, In‐Hye Ham, (unknown), (unknown), Zhang Zhang, Ke Ding, Hoon Hur	3
9	Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations 2023 ·Journal of Medicinal Chemistry ·(unknown), Jie Wang, Yongjin Wang, (unknown), (unknown), (unknown), Xiaojuan Song, Zhengchao Tu, Yang Zhou, Ke Ding, Zhimin Zhang, Zhang Zhang, Xiaoyun Lu	10
10	Ynamide Electrophile for the Profiling of Ligandable Carboxyl Residues in Live Cells and the Development of New Covalent Inhibitors 2022 ·Journal of Medicinal Chemistry ·Shengrong Li, Pengwei Zhang, Fang Xu, (unknown), Jia-Cong Liu, Yi Tan, Zhengchao Tu, Hongyan Sun, Zhimin Zhang, Qing‐Yu He, Pinghua Sun, Ke Ding, Zhengqiu Li	25
11	Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors 2022 ·Journal of Medicinal Chemistry ·(unknown), Yunong Zhang, (unknown), (unknown), Peng Xia, Jian Zou, Licheng Zhou, Li Tan, (unknown), Yang Zhou, Hoon Hur, Jing Ai, Zhen Wang, Xiaomei Ren, Zhang Zhang, Ke Ding	15
12	GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo 2021 ·Cancer Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Xiaojuan Song, Zhengchao Tu, Yuting Wang, Xiaomei Ren, Ke Ding, Zhang Zhang	17
13	Quantitative Proteomics Reveals Cellular Off-Targets of a DDR1 Inhibitor 2020 ·ACS Medicinal Chemistry Letters ·(unknown), Zhang Zhang, Ligen Lin, Hongyan Sun, Lorenzo V. White, Ke Ding, Zhengqiu Li	10
14	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma 2017 ·Molecular Cancer Therapeutics ·Kristina Y. Aguilera, Huocong Huang, Wenting Du, (unknown), Zhen Wang, Stefan Hinz, Tae Hyun Hwang, Huamin Wang, Jason B. Fleming, Diego H. Castrillón, Xiaomei Ren, Ke Ding, Rolf A. Brekken	88
15	Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia 2016 ·Clinical Cancer Research ·Bei Jin, Chengyan Wang, Juan Li, Xin Du, Ke Ding, Jingxuan Pan	53
16	Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing β-Catenin Signaling 2014 ·Molecular Cancer Therapeutics ·Bei Jin, Ke Ding, Jingxuan Pan	36
17	Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor α and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells 2012 ·Clinical Cancer Research ·Yongbin Wu, (unknown), Xiaoyong Sun, Xianping Shi, Bei Jin, Ke Ding, Sai‐Ching J. Yeung, Jingxuan Pan	42
18	Inhibition of TGF-β1-induced extracellular matrix production in primary human pulmonary fibroblasts by rapamycin 2011 ·European Respiratory Journal ·Yu Gao, Huaping Dai, Xuefeng Xu, Ke Ding	1
19	Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem Cells: Inactivation of the NF-κB Pathway and Generation of Reactive Oxygen Species 2010 ·Cancer Research ·Yanli Jin, Zhongzheng Lu, Ke Ding, Juan Li, Xin Du, Chun Chen, Xiaoyong Sun, Yongbin Wu, Jing Zhou, Jingxuan Pan	261
20	Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer 2008 ·Molecular Cancer Therapeutics ·Sanjeev Shangary, Ke Ding, Su Qiu, Zaneta Nikolovska‐Coleska, Joshua A. Bauer, Meilan Liu, Guoping Wang, Yipin Lu, Donna McEachern, Denzil Bernard, Carol R. Bradford, Thomas E. Carey, Shaomeng Wang	75

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact